Startups Plan the Health Data Gold Rush
Startups Plan the Health Data Gold Rush
Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.
Startups Plan the Health Data Gold Rush
Startups Plan the Health Data Gold Rush

Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.

Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.

Bio Business
New ALS Therapies Move Closer to the ClinicNew ALS Therapies Move Closer to the Clinic
New ALS Therapies Move Closer to the Clinic
Jenny Rood | Sep 1, 2018
After two decades of failure, novel scientific insights and technical progress are spurring meaningful innovation in the field.
Bringing the Internet of Things into the Lab
Bringing the Internet of Things into the Lab
Abby Olena | Jun 1, 2018
The IoT can link up many facets of research—from laboratory equipment to ideas—but scientists must be ready for the questions its implementation could raise.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
The Quest for Safer Opioid Drugs
The Quest for Safer Opioid Drugs
Jenny Rood | Jan 1, 2018
From basic research in academic labs to Phase 3 clinical trials, myriad efforts are underway to divorce opioids' pain-relieving potential from their undesirable downsides.
Flux and Uncertainty in the CRISPR Patent Landscape
Flux and Uncertainty in the CRISPR Patent Landscape
Aggie Mika | Oct 1, 2017
The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.
Accessing Drugs for Medical Aid-in-Dying
Accessing Drugs for Medical Aid-in-Dying
Catherine Offord | Aug 16, 2017
A fraught market for the barbiturates prescribed to terminally ill patients who choose to end their lives has physicians turning to options outside big pharma.
Learning from Iceland’s Model for Genetic Research
Learning from Iceland’s Model for Genetic Research
Catherine Offord | Jun 1, 2017
The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.
Making CAR T-Cell Therapy Safer
Making CAR T-Cell Therapy Safer
Catherine Offord | Apr 1, 2017
Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.
Pharma Cooperates to Achieve Precision Medicine
Pharma Cooperates to Achieve Precision Medicine
Catherine Offord | Feb 1, 2017
The challenges of adapting drug development to the age of personalized therapies encourage collaboration among industry players.